The new agreement will use Caprion’s CellCarta proteomics discovery platform which comprehensively profiles the expression and identity of proteins detected in tissues and blood plasma.
The company is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies.
“Caprion looks forward to building on the successful tumor antigen target discovery collaboration initiated with Icos last year with this second collaboration in the area of biomarkers,” noted Dr Daniel Chelsky, Caprion’s chief scientific officer. “We believe that this signals Icos’ confidence in Caprion’s ability to discover protein biomarkers that will have a positive impact on their oncology development programs.”
Caprion is a drug discovery and development company focused in oncology and infectious disease. Its most advanced program will enter phase II clinical trials in the US for Shiga-toxin producing E coli infection in the third quarter of 2006.